BA/BE of Biologics & Biosimilars
A biosimilar is a biologic therapeutic item which is duplicate of a unique item that is produced by an alternate organization. Biosimilars are authoritatively sanction forms of unique "discoverer" items, and can be produced when the first item's patent terminates. Reference to the pioneer item is a fundamental part of the approbation.
The world market of biosimilars is predicted to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3%. The market is classified into product, manufacturing type, application, and region. According to the application, the divisions in the biosimilars market are oncology, chronic and autoimmune diseases, blood disorders, infectious diseases, growth hormone deficiency and other applications.
- Cancer therapeutics
- Cardiovascular therapeutics
- Diabetes therapeutics
- Adverse drug reactions with pharmaceutical products
- Bioanalytical Approaches
Related Conference of BA/BE of Biologics & Biosimilars
BA/BE of Biologics & Biosimilars Conference Speakers
Recommended Sessions
- Advances in BABE
- Assessment of Bioequivalence
- BA/BE of Biologics & Biosimilars
- Bioavailability Studies
- Bioequivalence Protocols : In vivo/ In vitro studies
- Bioequivalence Studies
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Clinical Trials
- Contract Research Organizations
- Factors Affecting Bioavailability
- Managing BA/BE Studies
- Nutrient Bioavailability
- Pharma Clinical Trials
- Pharmaceutical Industry: Entrepreneurs Investment Meet
- Regulatory Requirements for Bioequivalence
- Significance of BA/BE Studies
- Study Designs